Pelthos Therapeutics Net Income
| PTHS Stock | 22.51 0.43 1.95% |
As of the 11th of February 2026, Pelthos Therapeutics holds the Risk Adjusted Performance of (0.08), coefficient of variation of (857.15), and Variance of 27.72. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pelthos Therapeutics, as well as the relationship between them. Please check Pelthos Therapeutics information ratio and kurtosis to decide if Pelthos Therapeutics is priced some-what accurately, providing market reflects its current price of 22.51 per share. Given that Pelthos Therapeutics has information ratio of (0.13), we recommend you to check out Pelthos Therapeutics's recent market performance to make sure the company can sustain itself at a future point.
Pelthos Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Pelthos Therapeutics' valuation are provided below:There are over ninety-one available trending fundamental ratios for Pelthos Therapeutics, which can be analyzed over time and compared to other ratios. All traders should check out Pelthos Therapeutics' recent fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -7.2 M | -7.5 M | |
| Net Loss | -7.2 M | -7.5 M | |
| Net Loss | (15.57) | (14.79) |
Pelthos | Net Income | Build AI portfolio with Pelthos Stock |
The evolution of Net Income for Pelthos Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Pelthos Therapeutics compares to historical norms and industry peers.
Latest Pelthos Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Pelthos Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Pelthos Therapeutics financial statement analysis. It represents the amount of money remaining after all of Pelthos Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Pelthos Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pelthos Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (7.96 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Pelthos Net Income Regression Statistics
| Arithmetic Mean | (2,330,479) | |
| Coefficient Of Variation | (124.25) | |
| Mean Deviation | 2,365,170 | |
| Median | (660,584) | |
| Standard Deviation | 2,895,696 | |
| Sample Variance | 8.4T | |
| Range | 7.4M | |
| R-Value | (0.77) | |
| Mean Square Error | 3.7T | |
| R-Squared | 0.59 | |
| Significance | 0.0003 | |
| Slope | (438,702) | |
| Total Sum of Squares | 134.2T |
Pelthos Net Income History
Other Fundumenentals of Pelthos Therapeutics
Pelthos Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Pelthos Therapeutics is extremely important. It helps to project a fair market value of Pelthos Stock properly, considering its historical fundamentals such as Net Income. Since Pelthos Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pelthos Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pelthos Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Pharmaceuticals market expansion? Will Pelthos introduce new products? Factors like these will boost the valuation of Pelthos Therapeutics. Anticipated expansion of Pelthos directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Pelthos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pelthos Therapeutics is measured differently than its book value, which is the value of Pelthos that is recorded on the company's balance sheet. Investors also form their own opinion of Pelthos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pelthos Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Pelthos Therapeutics' market value can be influenced by many factors that don't directly affect Pelthos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Pelthos Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pelthos Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Pelthos Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Pelthos Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pelthos Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pelthos Therapeutics.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Pelthos Therapeutics on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Pelthos Therapeutics or generate 0.0% return on investment in Pelthos Therapeutics over 90 days. Pelthos Therapeutics is related to or competes with CASI Pharmaceuticals, Lisata Therapeutics, Kairos Pharma, Lexaria Bioscience, Passage Bio, Lixte Biotechnology, and Enlivex Therapeutics. Pelthos Therapeutics is entity of United States More
Pelthos Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pelthos Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pelthos Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 25.75 | |||
| Value At Risk | (8.07) | |||
| Potential Upside | 8.39 |
Pelthos Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pelthos Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pelthos Therapeutics' standard deviation. In reality, there are many statistical measures that can use Pelthos Therapeutics historical prices to predict the future Pelthos Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.67) | |||
| Total Risk Alpha | (1.17) | |||
| Treynor Ratio | (1.25) |
Pelthos Therapeutics February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (1.24) | |||
| Mean Deviation | 3.99 | |||
| Coefficient Of Variation | (857.15) | |||
| Standard Deviation | 5.27 | |||
| Variance | 27.72 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.67) | |||
| Total Risk Alpha | (1.17) | |||
| Treynor Ratio | (1.25) | |||
| Maximum Drawdown | 25.75 | |||
| Value At Risk | (8.07) | |||
| Potential Upside | 8.39 | |||
| Skewness | 0.4384 | |||
| Kurtosis | 0.6866 |
Pelthos Therapeutics Backtested Returns
Pelthos Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.12, which implies the firm had a -0.12 % return per unit of risk over the last 3 months. Pelthos Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Pelthos Therapeutics' Risk Adjusted Performance of (0.08), variance of 27.72, and Coefficient Of Variation of (857.15) to confirm the risk estimate we provide. The company holds a Beta of 0.5, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pelthos Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Pelthos Therapeutics is expected to be smaller as well. At this point, Pelthos Therapeutics has a negative expected return of -0.59%. Please make sure to check Pelthos Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Pelthos Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.57 |
Modest predictability
Pelthos Therapeutics has modest predictability. Overlapping area represents the amount of predictability between Pelthos Therapeutics time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pelthos Therapeutics price movement. The serial correlation of 0.57 indicates that roughly 57.0% of current Pelthos Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.57 | |
| Spearman Rank Test | 0.53 | |
| Residual Average | 0.0 | |
| Price Variance | 4.64 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Pelthos Operating Income
Operating Income |
|
Based on the recorded statements, Pelthos Therapeutics reported net income of (7.96 Million). This is 102.33% lower than that of the Pharmaceuticals sector and 111.36% lower than that of the Health Care industry. The net income for all United States stocks is 101.39% higher than that of the company.
Pelthos Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pelthos Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pelthos Therapeutics could also be used in its relative valuation, which is a method of valuing Pelthos Therapeutics by comparing valuation metrics of similar companies.Pelthos Therapeutics is currently under evaluation in net income category among its peers.
Pelthos Fundamentals
| EBITDA | (7.17 M) | ||||
| Net Income | (7.96 M) | ||||
| Total Debt | 2.19 M | ||||
| Cash Flow From Operations | (5.79 M) | ||||
| Total Asset | 1.37 M | ||||
| Retained Earnings | (21.47 M) | ||||
| Working Capital | (2.71 M) | ||||
| Net Asset | 1.37 M |
About Pelthos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pelthos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pelthos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pelthos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pelthos Stock Analysis
When running Pelthos Therapeutics' price analysis, check to measure Pelthos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pelthos Therapeutics is operating at the current time. Most of Pelthos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pelthos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pelthos Therapeutics' price. Additionally, you may evaluate how the addition of Pelthos Therapeutics to your portfolios can decrease your overall portfolio volatility.